Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorTraversi, Letizia
dc.contributor.authorMiravitlles Fernández, Marc
dc.contributor.authorShteinberg, Michal
dc.contributor.authorBossios, Apostolos
dc.contributor.authorDimakou, Katerina
dc.contributor.authorPolverino, Eva
dc.contributor.authorMartinez-Garcia, Miguel Angel
dc.date.accessioned2022-06-28T11:00:59Z
dc.date.available2022-06-28T11:00:59Z
dc.date.issued2021-10-01
dc.identifier.citationTraversi L, Miravitlles M, Martinez-Garcia MA, Shteinberg M, Bossios A, Dimakou K, et al. ROSE: radiology, obstruction, symptoms and exposure – a Delphi consensus definition of the association of COPD and bronchiectasis by the EMBARC Airways Working Group. ERJ Open Res. 2021 Oct 1;7(4):00399–2021.
dc.identifier.issn2312-0541
dc.identifier.urihttps://hdl.handle.net/11351/7744
dc.descriptionConsensus; COPD; Clinical practice
dc.description.abstractIntroduction The coexistence of COPD and bronchiectasis seems to be common and associated with a worse prognosis than for either disease individually. However, no definition of this association exists to guide researchers and clinicians. Methods We conducted a Delphi survey involving expert pulmonologists and radiologists from Europe, Turkey and Israel in order to define the “COPD– [bronchiectasis] BE association”. A panel of 16 experts from EMBARC selected 35 statements for the survey after reviewing scientific literature. Invited participants, selected on the basis of expertise, geographical and sex distribution, were asked to express agreement on the statements. Consensus was defined as a score of ≥6 points (scale 0 to 9) in ≥70% of answers across two scoring rounds. Results 102 (72.3%) out of 141 invited experts participated in the first round. Their response rate in the second round was 81%. The final consensus definition of “COPD–BE association” was: “The coexistence of (1) specific radiological findings (abnormal bronchial dilatation, airways visible within 1 cm of pleura and/or lack of tapering sign in ≥1 pulmonary segment and in >1 lobe) with (2) an obstructive pattern on spirometry ([forced expiratory volume in 1 s] FEV1/[forced vital capacity] FVC <0.7), (3) at least two characteristic symptoms (cough, expectoration, dyspnoea, fatigue, frequent infections) and (4) current or past exposure to smoke (≥10 pack-years) or other toxic agents (biomass, etc.)”. These criteria form the acronym “ROSE” (Radiology, Obstruction, Symptoms, Exposure). Conclusions The Delphi process formulated a European consensus definition of “COPD–BE association”. We hope this definition will have broad applicability across clinical practice and research in the future.
dc.language.isoeng
dc.publisherEuropean Respiratory Society
dc.relation.ispartofseriesERJ Open Research;7(4)
dc.rightsAttribution-NonCommercial 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/
dc.sourceScientia
dc.subjectPulmons - Malalties obstructives
dc.subjectBronquièctasi
dc.subjectEnquestes
dc.subject.meshDelphi Technique
dc.subject.meshBronchiectasis
dc.subject.meshPulmonary Disease, Chronic Obstructive
dc.titleROSE: radiology, obstruction, symptoms and exposure – a Delphi consensus definition of the association of COPD and bronchiectasis by the EMBARC Airways Working Group
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1183/23120541.00399-2021
dc.subject.decstécnica Delfos
dc.subject.decsbronquiectasia
dc.subject.decsenfermedad pulmonar obstructiva crónica
dc.relation.publishversionhttp://dx.doi.org/10.1183/23120541.00399-2021
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Traversi L] Dept of Medicine and Surgery, Respiratory Diseases, Università dell’Insubria, Varese-Como, Italy. Servei de Pneumologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. [Miravitlles M] Servei de Pneumologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. CIBER de Enfermedades Respiratorias, Barcelona, Spain. [Martinez-Garcia MA] CIBER de Enfermedades Respiratorias, Barcelona, Spain. Respiratory Dept, La Fe University and Polytechnic Hospital, Valencia, Spain. [Shteinberg M] Pulmonology Institute and Cystic Fibrosis Center, Carmel Medical Center, and the Technion – Israel Institute of Technology, the B. Rappaport Faculty of Medicine, Haifa, Israel. [Bossios A] Dept of Respiratory Medicine and Allergy, Karolinska University Hospital and Dept of Medicine, Karolinska Institutet, Stockholm, Sweden. [Dimakou K] 5th Respiratory Department, “SOTIRIA” Hospital for Chest diseases, Athens, Greece. [Polverino E] Servei de Pneumologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain
dc.identifier.pmid34820447
dc.identifier.wos000769759500037
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record